The National Institute for Health and Care Excellence (NICE) has recently approved Vabysmo▼(faricimab) for treating adults with visual impairment due to macular oedema secondary to branch and central retinal vein occlusion (BRVO and CRVO). The NICE approval of Vabysmo was based on safety and efficacy data across two phase III studies in RVO – BALATON and COMINO.
In response to the news, Eelke Roos, Ophthalmology Lead at Roche Products Limited, said: “We are delighted with the news that people in England and Wales with macular oedema as a result of retinal vein occlusion will have access to Vabysmo. In England and Wales, it is estimated that each year, about 11,600 people with macular oedema due to BRVO and 5,700 people with macular oedema due to CRVO experience visual problems1.”
▼ This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions.
Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Roche Products Ltd. Please contact Roche Drug Safety Centre by emailing welwyn.uk_dsc@roche.com or calling +44 (0)1707 367554.
Date of preparation: September 2024 | M-GB-00019475
References
1. The Royal College of Ophthalmologists (RCOphth), 2022, Retinal Vein Occlusion (RVO) Guidelines. Available at https://www.rcophth.ac.uk/wp-content/uploads/2015/07/Retinal-Vein-Occlusion-Guidelines-2022.pdf
FURTHER INFORMATION:
